Tumor Ablation Market—Forecast till 2030

Table of Contents

TABLE OF CONTENTS 1 EXECUTIVE SUMMARY 15 1.1.1 MARKET SYNOPSIS 15 2 MARKET INTRODUCTION 16 2.1 SCOPE OF THE STUDY 16 2.2 RESEARCH OBJECTIVE 16 2.3 LIST OF ASSUMPTIONS & LIMITATIONS 16 3 RESEARCH METHODOLOGY 18 3.1 DATA MINING 18 3.2 SECONDARY RESEARCH 19 3.3 PRIMARY RESEARCH 20 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 20 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS 21 3.4 FORECASTING TECHNIQUES 21 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22 3.5.1 BOTTOM-UP APPROACH 23 3.5.2 TOP-DOWN APPROACH 24 3.6 DATA TRIANGULATION 24 3.7 VALIDATION 24 4 MARKET DYNAMICS 26 4.1 OVERVIEW 26 4.2 DRIVERS 27 4.2.1 INCREASING PREVALENCE OF CANCER ACROSS THE GLOBE 27 4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE TUMOR ABLATION TECHNIQUES 27 4.2.3 GROWING NUMBER OF PUBLIC-PRIVATE INITIATIVES AND FUNDING TO SUPPORT ONGOING RESEARCH ACTIVITIES RELATED TO TUMOR ABLATION 27 4.3 RESTRAINTS 28 4.3.1 SIDE-EFFECTS AND COMPLICATIONS ASSOCIATED WITH TUMOR ABLATION 28 4.3.2 DELAY IN APPROVAL AND UNFAVORABLE REGULATORY POLICY AND REIMBURSEMENT SCENARIO 28 4.4 OPPORTUNITY 29 4.4.1 RISING R&D ACTIVITIES 29 5 MARKET FACTOR ANALYSIS 30 5.1 VALUE CHAIN ANALYSIS 30 5.1.1 R&D 31 5.1.2 MANUFACTURING 31 5.1.3 DISTRIBUTION & SALES 31 5.1.4 POST-SALES MONITORING 31 5.2 PORTER'S FIVE FORCES ANALYSIS 32 5.2.1 THREAT OF NEW ENTRANTS 33 5.2.2 BARGAINING POWER OF SUPPLIERS 33 5.2.3 BARGAINING POWER OF BUYERS 33 5.2.4 THREAT OF SUBSTITUTES 33 5.2.5 INTENSITY OF RIVALRY 33 5.3 COVID-19 IMPACT ANALYSIS 34 5.3.1 IMPACT ON AVAILABILITY OF SURGICAL FACILITIES 34 5.3.2 IMPACT ON KEY PLAYERS 34 5.3.3 IMPACT ON CLINICAL TRIALS 35 5.3.4 IMPACT ON SUPPLY CHAIN 35 6 GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY 36 6.1 OVERVIEW 36 6.2 RADIOFREQUENCY 37 6.3 MICROWAVE 37 6.4 IRREVERSIBLE ELECTROPORATION 38 6.5 CRYOABLATION 39 6.6 OTHERS 40 7 GLOBAL TUMOR ABLATION MARKET, BY TREATMENT 41 7.1 OVERVIEW 41 7.2 SURGICAL ABLATION 42 7.3 PERCUTANEOUS ABLATION 42 7.4 LAPAROSCOPIC ABLATION 43 8 GLOBAL TUMOR ABLATION MARKET, BY APPLICATION 44 8.1 OVERVIEW 44 8.2 LUNG CANCER 45 8.3 KIDNEY CANCER 45 8.4 LIVER CANCER 46 8.5 OTHERS 47 9 GLOBAL TUMOR ABLATION MARKET, BY END USER 48 9.1 OVERVIEW 48 9.2 HOSPITAL AND CLINICS 49 9.3 SPECIALITY CENTERS 50 9.4 OTHERS 50 10 GLOBAL TUMOR ABLATION MARKET, BY REGION 51 10.1 OVERVIEW 51 10.2 NORTH AMERICA 52 10.2.1 US 55 10.2.2 CANADA 56 10.3 EUROPE 58 10.3.1 GERMANY 61 10.3.2 FRANCE 62 10.3.3 UK 63 10.3.4 ITALY 65 10.3.5 SPAIN 66 10.3.6 REST OF EUROPE 67 10.4 ASIA PACIFIC 69 10.4.1 CHINA 71 10.4.2 INDIA 72 10.4.3 JAPAN 74 10.4.4 SOUTH KOREA 75 10.4.5 AUSTRALIA 76 10.4.6 REST OF ASIA PACIFIC 78 10.5 REST OF THE WORLD 80 10.5.1 MIDDLE EAST 82 10.5.2 AFRICA 84 10.5.3 LATIN AMERICA 85 11 COMPETITIVE LANDSCAPE 87 11.1 OVERVIEW 87 11.2 COMPETITIVE BENCHMARKING 88 11.3 MAJOR GROWTH STRATEGY IN THE GLOBAL TUMOR ABLATION MARKET 89 11.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL TUMOR ABLATION MARKET 90 11.5 KEY DEVELOPMENT ANALYSIS 90 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES 91 11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL 91 11.6.2 MERGER &ACQUISITION 91 11.7 FINANCIAL MATRIX 92 11.7.1 SALES (USD MILLION), 2020 92 11.7.2 R&D EXPENDITURE (USD MILLION), 2020 92 12 DRG COST OF CURATIVE TREATMENT 93 12.1 DIAGNOSIS-RELATED GROUP (DRG) 93 12.2 BIOPSY PROCEDURE REIMBURSEMENT 93 12.3 ABLATION PROCEDURE REIMBURSMENT 93 12.3.1 LIVER ABLATION PROCEDURE REIMBURSMENT 94 12.3.2 KIDNEY ABLATION PROCEDURE REIMBURSMENT 94 12.3.3 LUNG ABLATION PROCEDURE REIMBURSMENT 95 12.4 IMAGING PROCEDURE REIMBURSMENT 95 12.5 TOTAL CURATIVE TREATMENT COSTS 96 13 COMPANY PROFILES 97 13.1 SONACARE MEDICAL 97 13.1.1 COMPANY OVERVIEW 97 13.1.2 FINANCIAL OVERVIEW 97 13.1.3 PRODUCTS/SERVICES OFFERED 97 13.1.4 KEY DEVELOPMENTS 97 13.1.5 SWOT ANALYSIS 98 13.1.6 KEY STRATEGIES 98 13.2 MEDTRONIC PLC 99 13.2.1 COMPANY OVERVIEW 99 13.2.2 FINANCIAL OVERVIEW 99 13.2.3 PRODUCTS/SERVICES OFFERED 100 13.2.4 KEY DEVELOPMENTS 100 13.2.5 SWOT ANALYSIS 100 13.2.6 KEY STRATEGIES 101 13.3 EDAP TMS 102 13.3.1 COMPANY OVERVIEW 102 13.3.2 FINANCIAL OVERVIEW 102 13.3.3 PRODUCTS/SERVICES OFFERED 103 13.3.4 KEY DEVELOPMENTS 103 13.3.5 SWOT ANALYSIS 103 13.3.6 KEY STRATEGIES 103 13.4 ANGIODYNAMICS 104 13.4.1 COMPANY OVERVIEW 104 13.4.2 FINANCIAL OVERVIEW 104 13.4.3 PRODUCTS/SERVICES OFFERED 105 13.4.4 KEY DEVELOPMENTS 105 13.4.5 SWOT ANALYSIS 105 13.4.6 KEY STRATEGIES 105 13.5 HEALTHTRONICS, INC. 106 13.5.1 COMPANY OVERVIEW 106 13.5.2 FINANCIAL OVERVIEW 106 13.5.3 PRODUCTS/SERVICES OFFERED 106 13.5.4 KEY DEVELOPMENTS 106 13.5.5 SWOT ANALYSIS 107 13.5.6 KEY STRATEGIES 107 13.6 JOHNSON & JOHNSON 108 13.6.1 COMPANY OVERVIEW 108 13.6.2 FINANCIAL OVERVIEW 108 13.6.3 PRODUCTS/SERVICES OFFERED 109 13.6.4 KEY DEVELOPMENTS 109 13.6.5 SWOT ANALYSIS 109 13.6.6 KEY STRATEGIES 109 13.7 BOSTON SCIENTIFIC CORPORATION 110 13.7.1 COMPANY OVERVIEW 110 13.7.2 FINANCIAL OVERVIEW 110 13.7.3 PRODUCTS/SERVICES OFFERED 111 13.7.4 KEY DEVELOPMENTS 111 13.7.5 SWOT ANALYSIS 111 13.7.6 KEY STRATEGIES 112 13.8 MISONIX, INC. 113 13.8.1 COMPANY OVERVIEW 113 13.8.2 FINANCIAL OVERVIEW 113 13.8.3 PRODUCTS/SERVICES OFFERED 114 13.8.4 KEY DEVELOPMENTS 114 13.8.5 SWOT ANALYSIS 114 13.8.6 KEY STRATEGIES 115 13.9 HISTOSONICS, INC. 116 13.9.1 COMPANY OVERVIEW 116 13.9.2 FINANCIAL OVERVIEW 116 13.9.3 PRODUCTS/SERVICES OFFERED 116 13.9.4 KEY DEVELOPMENTS 116 13.9.5 SWOT ANALYSIS 117 13.9.6 KEY STRATEGIES 117 13.10 BIOTRONIK 118 13.10.1 COMPANY OVERVIEW 118 13.10.2 FINANCIAL OVERVIEW 118 13.10.3 PRODUCTS/SERVICES OFFERED 118 13.10.4 KEY DEVELOPMENTS 118 13.10.5 SWOT ANALYSIS 119 13.10.6 KEY STRATEGIES 119 14 APPENDIX 120 14.1 REFERENCES 120 14.2 RELATED REPORTS 120